Media headlines about Eagle Pharmaceuticals (NASDAQ:EGRX) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 45.4765808124727 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

EGRX has been the subject of a number of recent analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $75.00 price objective (down previously from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. ValuEngine lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 2nd. Finally, Mizuho reaffirmed a “sell” rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Eagle Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $62.33.

Eagle Pharmaceuticals (NASDAQ EGRX) opened at $57.52 on Wednesday. Eagle Pharmaceuticals has a 52 week low of $45.05 and a 52 week high of $97.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15. The company has a market cap of $858.29, a P/E ratio of 9.17 and a beta of 1.24.

COPYRIGHT VIOLATION NOTICE: “Eagle Pharmaceuticals (EGRX) Receives Media Impact Score of 0.19” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/eagle-pharmaceuticals-egrx-receives-media-impact-score-of-0-19/1760554.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.